Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes?

If you answer YES to any of the above, now is the time to register for the AIMday in Antimicrobial Resistance.

The event takes place on Thursday 4 July at the Blavatnik School of Government and is hosted by The University of Oxford, together with the NIHR Community Healthcare MIC.

FREE registration for academics is now open and closes on Thursday 27 June (advance registration is essential).

A range of companies are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions.

Companies registered to attend

  • Abbott
  • Academic Health Science Network for the North East and North Cumbria
  • Amprologix
  • Astrego Diagnostics
  • Centauri Therapeutics
  • Destiny Pharma
  • Evotec
  • GeneFirst
  • GSK
  • Ingenza
  • Innovate UK
  • metaLinear
  • Oppilotech
  • Oxford Drug Design
  • Pedanius Therapeutics
  • Randox Laboratories
  • Release Life Sciences and Diagnostics
  • Summit Therapeutics
  • Thermo Fisher Scientific

To see the questions posed by these companies, please visit aimday.se/amr-2019/questions-listing.

Register here: http://aimday.se/amr-oxford-2019

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.